Equities Analysts Issue Forecasts for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Wedbush cut their FY2025 earnings estimates for Travere Therapeutics in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.74) for the year, down from their previous estimate of ($0.69). Wedbush has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ Q4 2025 earnings at ($0.08) EPS and Q1 2026 earnings at ($0.05) EPS.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.08. The company had revenue of $81.73 million during the quarter, compared to analysts’ expectations of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. Travere Therapeutics’s quarterly revenue was up 83.3% on a year-over-year basis. During the same period last year, the company posted ($1.76) earnings per share.

Several other equities analysts have also recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Bank of America lifted their price objective on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Scotiabank reissued an “outperform” rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Stifel Nicolaus lifted their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 2nd. Finally, Citigroup dropped their price objective on shares of Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.14.

Travere Therapeutics Stock Performance

TVTX opened at $16.11 on Thursday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -5.73 and a beta of 0.72. The company has a fifty day moving average of $15.87 and a 200 day moving average of $18.06. Travere Therapeutics has a fifty-two week low of $7.93 and a fifty-two week high of $25.29. The company has a debt-to-equity ratio of 9.46, a quick ratio of 2.03 and a current ratio of 2.05.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. GF Fund Management CO. LTD. bought a new stake in Travere Therapeutics during the 4th quarter valued at about $31,000. Sterling Capital Management LLC lifted its holdings in Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after buying an additional 2,115 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Travere Therapeutics during the 1st quarter valued at about $62,000. Gen Wealth Partners Inc bought a new stake in Travere Therapeutics during the 4th quarter valued at about $73,000. Finally, KBC Group NV bought a new stake in Travere Therapeutics during the 1st quarter valued at about $75,000.

Insider Buying and Selling

In related news, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the transaction, the chief financial officer directly owned 93,126 shares of the company’s stock, valued at approximately $1,960,302.30. The trade was a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 18,924 shares of Travere Therapeutics stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $398,350.20. Following the transaction, the chief executive officer directly owned 419,173 shares of the company’s stock, valued at approximately $8,823,591.65. This represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,294 shares of company stock valued at $485,123. Company insiders own 4.19% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.